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    ABSTRACT   
  Objectives      To evaluate the risk of septic arthritis (SA) in 
patients with rheumatoid arthritis (RA) treated with anti-
tumour necrosis factor (TNF) therapy.   
  Methods      Using data from the British Society for 
Rheumatology Biologics Register, a prospective 
observational study, the authors compared the risk of SA 
between 11 881 anti-TNF-treated and 3673 non-biological 
disease-modifying antirheumatic drug (nbDMARD)-
treated patients.   
  Results      199 patients had at least one episode of SA 
(anti-TNF: 179, nbDMARD: 20). Incidence rates were: 
anti-TNF 4.2/1000 patient years (pyrs) follow-up (95% 
CI 3.6 to 4.8), nbDMARD 1.8/1000 pyrs (95% CI 1.1 to 
2.7). The adjusted HR for SA in the anti-TNF cohort was 
2.3 (95% CI 1.2 to 4.4). The risk did not differ signiﬁ  cantly 
between the three agents: adalimumab, etanercept and 
inﬂ  iximab. The risk was highest in the early months of 
therapy. The patterns of reported organisms differed in 
the anti-TNF cohort. Prior joint replacement surgery was a 
risk factor for SA in all patients. The rate of postoperative 
joint infection (within 90 days of surgery) was 0.7%. This 
risk was not signiﬁ  cantly inﬂ  uenced by anti-TNF therapy.   
  Conclusions      Anti-TNF therapy use in RA is associated 
with a doubling in the risk of SA. Physicians and surgeons 
assessing the RA patient should be aware of this 
potentially  life-threatening  complication.      
  INTRODUCTION 
  Septic arthritis (SA) is a serious medical condi-
tion that, even with prompt treatment, can lead 
to irreversible joint damage and has a death rate 
of around 10%.  1   The incidence of SA in the gen-
eral population is around 4–10 per 100 000 patient 
years (pyrs) and seems to be rising,  2     3   probably due 
to the combination of an ageing population and 
larger numbers of orthopaedic interventions. 
  Important risk factors for SA include increasing 
age, joint prosthesis, skin infection and pre-existing 
joint damage.  4     5   Patients with rheumatoid arthritis 
(RA) may have many of these risks combined with 
the use of immunosuppressive medications. The 
risk of SA in an RA patient, irrespective of therapy, 
is increased by 4–15-fold.  5     6   Although one might 
expect immunosuppressive therapy to increase 
the risk of SA, this has not been well studied. 
This question has been of increasing interest over 
the last decade since the emergence of biological 
therapies. Anti-tumour necrosis factor (anti-TNF) 
therapies were the ﬁ  rst class of biological agents to 
become established in routine RA care. Data have 
emerged suggesting that these drugs confer a small 
but signiﬁ  cant risk of serious infections, especially 
during the ﬁ  rst months of treatment.  7    –    9   It is also 
apparent that this risk differs by anatomical site 
and that there is increased susceptibility to certain 
pathogens.  9    –    11   
  There is very limited information regarding 
the effect of anti-TNF therapy on the risk of SA. 
Case reports have described patients on anti-TNF 
therapy developing SA as a multifocal disease or 
with unusual causative organisms.  12    –    14   Although 
case reports are a useful tool for raising questions, 
they cannot provide information regarding disease 
incidence or relative risk. An additional important 
question relates to the risk of SA following joint 
replacement surgery in anti-TNF-treated patients. 
  In 2001, the British Society for Rheumatology 
(BSR) established a national prospective cohort 
study of patients starting anti-TNF therapy for RA, 
the BSR Biologics Register (BSRBR). This is the 
largest register of its kind worldwide and includes 
detailed records of serious adverse events including 
SA occurring in patients receiving anti-TNF therapy 
as well as in a cohort of RA patients not exposed to 
anti-TNF therapy. 
  Our primary aim was to test the hypothesis that 
anti-TNF therapy increases the risk of SA com-
pared with non-biological disease-modifying anti-
rheumatic drug (nbDMARD) therapy. Secondary 
analysis considered whether anti-TNF therapy 
confers additional risk to patients who have joint 
replacement surgery either prior to starting therapy 
or during follow-up.   
  METHODS 
  The study commenced in 2001 alongside national 
recommendations within the UK that all RA patients 
prescribed anti-TNF therapy should be enrolled 
with the register.  15   Patients were recruited to the 
anti-TNF cohort from 2001 onwards. Three anti-
TNF agents were licensed for use in the UK during 
this period, with inﬂ  iximab (INF) and etanercept 
(ETN) being available from the start of the study, 
while the third drug, adalimumab (ADA), came 
into clinical practice in 2003. Recruitment targets of 
4000 patients for the ETN cohort were met in 2005, 
for INF in 2007 and for ADA in 2008. Before recruit-
ment targets were met, it was estimated that over 
80% of anti-TNF-treated patients with RA in the 
UK were registered on the BSRBR.  16   A comparison 
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cohort of patients with active RA (deﬁ  ned as having a 28-joint 
count disease activity score (DAS28) >4.2) was recruited in par-
allel. These patients were receiving an nbDMARD and were 
biologically naive. Patients prescribed biologics were recruited 
from across the UK (over 250 hospitals) whereas controls were 
recruited from 29 centres. These control centres reﬂ  ect a combi-
nation of secondary and tertiary care rheumatology centres dis-
tributed across the UK and are listed in full in the BSRBR control 
centre consortium supplementary data ﬁ  le. 
  Baseline  assessment 
  All patients in this study had a physician diagnosis of RA. 
Baseline information included demographics, disease dura-
tion, a measure of self-reported physical function (the Health 
Assessment Questionnaire (HAQ)  17  ), DAS28 score,  18   baseline 
steroid use, smoking history, baseline comorbidity and surgery, 
including prior joint replacement. For the purpose of this analy-
sis, we have considered only large joint replacements (shoulder, 
elbow, hip and knee) because when reviewing reports of small 
joint surgery, it was difﬁ  cult to distinguish between soft-tissue 
procedures and arthroplasty.   
  Follow-up 
  Follow-up information was collected from three sources. First, 
six monthly questionnaires were sent to the treating rheuma-
tologist for 3 years and annually thereafter. Second, data were 
collected directly from the patients six monthly   for their ﬁ  rst 
3 years of the study. Patients were provided with a hand-
held diary card to record details of all hospital attendances 
as well as new prescriptions. Details of joint replacements 
during follow-up were collected from these two sources. 
Third, all patients were ﬂ  agged with the UK National Health 
Service Information Centre, which informs the register of any 
deaths and the causes of deaths. All patients had to have at 
least one returned consultant follow-up questionnaire prior to 
31 December 2009.   
  Case  deﬁ  nition and veriﬁ  cation 
  This analysis was conﬁ   ned to serious cases of SA. ‘Serious’ 
infections were deﬁ   ned as those requiring intravenous anti-
biotics or hospitalisation, or those resulting in death. All seri-
ous infections reported to the BSRBR were followed up with 
requests for additional information from the treating clinician 
to gather information on the site of infection and microbiology 
results. All reported cases of SA were then veriﬁ  ed by a BSRBR 
clinician (JBG). 
  Events were ascribed to anti-TNF if they occurred while the 
patient was receiving anti-TNF therapy or within 90 days of the 
ﬁ  rst missed dose. Events were attributed to the most recent drug 
exposure in patients who switched anti-TNF therapy. Patients 
were censored from further follow-up after their ﬁ  rst episode 
of SA. Only one case of articular   Mycobacterium tuberculosis   was 
reported to the BSRBR, which has been described in a previous 
publication and is not included in this analysis.  19     
  Statistical  methods 
  Crude incidence rates were calculated as the number of epi-
sodes of SA per 1000 pyrs of follow-up. Cumulative hazards 
were compared between the different cohorts using a Nelson–
Aalen plot. A Cox model was used to calculate HR between 
the groups. Changes to the incidence rate over time in the anti-
TNF cohort were analysed using a spline model. Potential con-
founders were identiﬁ  ed prior to the analysis as variables that 
were either unbalanced between the nbDMARD and anti-TNF 
cohorts (age, gender, disease duration, DAS28, HAQ, steroid 
exposure, prior joint replacement, calendar year of entry into 
the study) or signiﬁ  cant predictors of infection (chronic obstruc-
tive pulmonary disease, diabetes). Adjustment for these poten-
tial confounders was made using propensity scores. The use 
of this method in observational studies has been described in 
detail previously.  20   
  In a secondary analysis, the inﬂ  uence of joint replacement 
was examined. Patients were entered into this analysis when 
they were at risk of a prosthetic infection (ie, from baseline if 
they had a prior joint replacement or at the date of surgery if 
they had a joint replacement during follow-up). An adjusted 
Cox proportional hazards model was used to compare rates 
between groups. The risk of postoperative infection following 
joint replacement surgery during active follow-up was analysed 
separately using adjusted logistic regression to compare the odds 
of developing an infection within 90 days of joint replacement 
surgery between anti-TNF and nbDMARD cohorts. Adjustment 
was made for the same confounders as identiﬁ  ed in the primary 
analysis. Missing baseline data were replaced using multiple 
imputations. All analysis was done using Stata 10.1 (StataCorp, 
College Station, Texas, USA). 
  Further details of the statistical methodology are presented in 
a data supplement online. 
  Ethics approval for this study was obtained in December 
2000 from the Multicentre Research Ethics Committee for the 
Northwest of England.     
  RESULTS 
  The baseline characteristics of the 15 554 patients included in 
the analysis are shown in   table 1  . Although both anti-TNF and 
nbDMARD groups had active RA, there were signiﬁ  cant differ-
ences at baseline. The patients receiving anti-TNF therapy were 
younger and proportionally more were women. The anti-TNF 
group had signiﬁ  cantly longer disease duration as well as higher 
disease activity. History of joint replacement was higher in the 
anti-TNF cohort (24% vs 14% (p<0.001)).   
  Incident SA was reported in 199 patients during the follow-
up period (179 anti-TNF; 20 nbDMARD). In univariate analy-
sis, increasing age, longer disease duration, higher HAQ, higher 
DAS28 score, baseline steroid exposure, prior orthopaedic sur-
gery and diabetes were associated with SA irrespective of anti-
TNF exposure. The strongest association was with a history of 
large joint orthopaedic surgery at baseline irrespective of whether 
the SA developed in a prosthetic joint: HR 2.45 (1.90–3.17). 
  The incident rate for SA was signiﬁ  cantly higher in the anti-
TNF cohort (4.2/1000 follow-up pyrs) than in the nbDMARD 
group (1.8/1000 pyrs) (  table 2  ). The cumulative incidence over 
time is presented in   ﬁ  gure 1  . The unadjusted HR for SA in the 
anti-TNF cohort was 2.5 (95% CI 1.6 to 4.0). After full adjust-
ment, patients on anti-TNF therapy were more than twice as 
likely to develop SA as the nbDMARD controls: adjusted HR 
2.3 (95% CI 1.2 to 4.4).     
  Hazard estimates for the ﬁ  rst year of follow-up were increased 
in all three anti-TNF agents; however, beyond 1 year, the hazard 
in the ETN cohort increased more than in the ADA and INF 
cohorts (  ﬁ  gure 1  ). The adjusted HR was highest within the ETN 
cohort and lowest for ADA (  table 2  ) although there were no 
differences between the three individual drugs or between the 
monoclonal antibody class and ETN that achieved statistical sig-
niﬁ  cance (results not shown). 
  The pattern of joint involvement was similar in the two 
cohorts with the knee being the most frequent site of infection 
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(anti-TNF 31%; nbDMARD 22%). Microbiological conﬁ  rmation 
was available for 94 (53%) of the anti-TNF cases and 7 (35%) 
of the DMARD cases.   Staphylococcus aureus   was the most fre-
quently reported organism in both cohorts (anti-TNF 57%; 
DMARD 43%). Six (11%) of the   S aureus   cases in the anti-TNF 
cohort were reported as being methicillin resistant. Also, within 
the anti-TNF cohort, several species that seldom cause joint 
infections were reported. These included ﬁ  ve cases of intracel-
lular infection (two   Listeria  , three   Salmonella  ) and four cases of 
  Pseudomonas aeruginosa   infection. Analysis of results limited to 
only culture-proven SA yielded an adjusted HR of 2.7 (95% CI 
1.0 to 6.9) for anti-TNF. 
  The hazard for SA in the anti-TNF cohort was greatest in 
the early months of therapy (  ﬁ  gure 2  ). This risk then decreased 
steadily over the remainder of the follow-up period. The 30-day 
all-cause mortality following SA was 6% (10/178) in the anti-
TNF cohort and 10% (2/20) in the DMARD cohort.   
  Forty-seven (24%) of the 199 cases were in prosthetic joints. 
In the patients with a history of large joint replacement (either 
at baseline or during follow-up), the incidence of prosthetic 
joint SA was not different between nbDMARD and anti-TNF 
cohorts (  table 3  ). Thirty of the 47 prosthetic joint SA cases 
occurred postoperatively (within 90 days of the joint replace-
ment surgery). In total, 4871 large joint replacements were per-
formed during the follow-up (nbDMARD 481; anti-TNF 4390). 
This equates to an incidence of SA within 90 days of surgery 
of 0.7% in the whole cohort. The adjusted OR for postop-
erative joint infection in the anti-TNF cohort compared with 
  nbDMARD was 0.8 (0.2–3.5).   
  DISCUSSION 
  Key questions remain unanswered from clinical trial data regard-
ing the safety of anti-TNF therapy, particularly with respect to rare 
outcomes including SA. This is the ﬁ  rst study to speciﬁ  cally exam-
ine the rate of SA in patients treated with anti-TNF therapy. We 
conﬁ  rmed our primary hypothesis that SA is increased in patients 
on anti-TNF therapy. However, these results must be interpreted 
with some important caveats. First, the absolute risk of SA remains 
very small, with an incident rate of only 4.2 per 1000 pyrs of 




 All  TNF 
(n=11 881)   p  Value *  
 Etanercept 
(n=4139) 
 Inﬂ  iximab 
(n=3475) 
 Adalimumab 
(n=4267)   p  Value †  
Age, mean (SD) 60 (12) 56 (12) <0.001 56 (12) 56 (12) 57 (12) 0.018
Sex (% female) 2652 (72) 9053 (76) <0.001 3193 (77) 2626 (76) 3234 (76) 0.203
DAS28 (mean (SD)) 5.1 (1.3) 6.6 (1.0) <0.001 6.6 (1.0) 6.6 (1.0) 6.5 (1.0) <0.001
HAQ score (mean (SD)) 1.5 (0.8) 2.0 (0.6) <0.001 2.1 (0.6) 2.1 (0.5) 1.9 (0.6) <0.001
Disease duration (years (median (IQR))) 6 (1, 15) 11 (6–19) <0.001 12 (6–19) 12 (6–19) 10(5–18) <0.001
Baseline steroid use (n (%)) 845 (23) 5228 (44) <0.001 1979 (48) 1609 (46) 1664 (39) <0.001
Diabetes (n (%)) 234 (6.7) 675 (5.8) 0.033 255 (6) 169 (4) 261 (6) 0.026
COPD (n (%)) 304 (8) 570 (5) <0.001 222 (5) 165 (5) 183 (4) 0.070
Smoking (n (%))
  Current 868 (24) 2580 (22) 0.001 846 (21) 757 (22) 977 (23) 0.029
  Ex 1454 (40) 4510 (38)   1576 (38) 1314 (38) 1620 (38)  
  Never 1333 (36) 4714 (40)   1691 (41) 1386 (40) 1637 (39)  
Prior large joint replacement (n (%))  ‡  521 (14) 2837 (24) <0.001 1090 (26) 846 (24) 901 (21) <0.001
Large joint replacement during follow-up 
(n (%))  ‡ 
481 (13) 4390 (37) <0.001 1907 (46) 1111 (32) 1372 (32) <0.001
      *    Represents the signiﬁ  cance of differences between the DMARD and anti-TNF cohorts using χ  2   tests for categorical outcomes and Wilcoxon rank sum tests for continuous variables.   
  †    Represents the signiﬁ  cance of differences between the three anti-TNF drugs using χ  2   tests for categorical outcomes and Kruskal–Wallis rank tests for continuous variables.   
  ‡    Elbow, shoulder, hip, knee and ankle.   
    Anti-TNF, anti-tumour necrosis factor; COPD, chronic obstructive pulmonary disease; DAS28, 28-joint count disease activity score; HAQ, Health Assessment Questionnaire; nbDMARD, 
non-biological disease-modifying antirheumatic drug.     
 Table  2        Risk of septic arthritis in patients with rheumatoid arthritis   
   nbDMARD   All  anti-TNF   Etanercept   Inﬂ  iximab   Adalimumab 
Exposure time (years) 11 426 42 671 18 554 10 827 13 289
Events (n) 20 179 86 41 52
Incident rate/1000 pyrs 
(95% CI)
1.8 (1.1 to 2.7) 4.2 (3.6 to 4.8) 4.6 (3.7 to 5.7) 3.8 (2.7 to 5.1) 3.9 (2.9 to 5.1)
Unadjusted HR (95% CI) Ref 2.5 (1.6 to 4.0) 3.0 (1.8 to 4.8) 2.2 (1.3 to 3.8) 2.3 (1.4 to 3.8)
Adjusted HR (95% CI) Ref 2.3 (1.2 to 4.4) 2.5 (1.3 to 4.9) 2.4 (1.0 to 5.8) 1.9 (0.9 to 4.0)
      Anti-TNF, anti-tumour necrosis factor; nbDMARD, non-biological disease-modifying antirheumatic drug; pyrs, patient years.     
 Figure  1     Nelson–Aalen plot comparing nbDMARD and anti-TNF 
cohorts. Anti-TNF, anti-tumour necrosis factor; nbDMARD, non-biological 
disease-modifying  antirheumatic  drug.    
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follow-up in the anti-TNF cohort. Second, given the observational 
nature of this study, it is important to recognise that differences 
exist between the nbDMARD and anti-TNF cohorts. Any differ-
ence in outcome between the two cohorts reﬂ  ects both the effect 
of the drug and the inherent differences in patient populations. The 
biologically treated cohort had, as expected, more severe disease 
at baseline and this is an important risk factor for the development 
of SA. We addressed this issue through adjustment using a propen-
sity model. The adjusted analysis continued to show a signiﬁ  cant 
increase in the risk of SA in the anti-TNF cohort (HR 2.3), which 
reﬂ  ects the risk attributable to the therapy itself. It is possible that 
there are unmeasured differences between the cohorts that we are 
unable to adjust for. 
  The point estimates showed the highest risk for SA in patients 
on ETN. However, this was not a hypothesis that we had set 
out to test. After adjusting for confounders, the 95% CIs for 
all three agents overlapped. Year of entry into the study is an 
important confounder when comparing between agents. We 
have recently published data from the BSRBR showing that 
both disease severity and recruitment patterns varied by calen-
dar year.  21   Therefore, it is not possible to draw ﬁ  rm conclusions 
about between-drug differences from these data. 
  As in the general population of RA patients, the most common 
aetiological organisms were   Staphylococcal   species. It is important 
to note that the organisms within the anti-TNF cohort included 
  Listeria   and   Salmonella  , both intracellular pathogens that rarely 
cause SA. This ﬁ  ts current understanding of the role of TNF in 
host defence and is in keeping with our previous reports of an 
increased risk of intracellular organisms (including   M tuberculosis  ) 
at all sites.  9     19   In the nbDMARD cohort, gram-negative species 
accounted for 50% of the organisms, which may reﬂ  ect the older 
age of the  nbDMARD cohort, whereas in the anti-TNF cohort, only 
10% of the reported species cultured were gram negative. This is 
of   relevance when considering antibiotic choices for patients with 
RA on anti-TNF therapy. Many guidelines for SA recommend 
antimicrobial therapy primarily aimed at   Staphylococcal   species and 
that lack activity against gram-negative organisms. 
  The risk of SA appeared to vary over time in the anti-TNF 
cohort. The ﬁ  nding of a greater risk early on in therapy has been 
described with other infections in our data as well as data from 
other cohorts.  22   There are a number of potential explanations for 
this early increased risk. First, it may reﬂ  ect a depletion of sus-
ceptible individuals from the exposed cohort. Second, it may 
reﬂ  ect a true reduction in risk of joint infection in patients who 
achieve better control of their RA. However, the data presented 
here do not allow deﬁ  nite conclusions to be made about these 
possibilities. 
  We also addressed the inﬂ  uence of orthopaedic surgery on 
the risk of SA. The BSR recommends that patients on anti-TNF 
therapy stop their treatment temporarily for 2–4 weeks prior to 
major surgical procedures and do not recommence therapy until 
wound healing is satisfactory.  23   Although it is not known with 
certainty how strictly physicians and patients adhere to these 
guidelines, in the context of this practice, it is very reassuring to 
see no evidence of an increased risk of prosthetic joint SA. 
  In summary, exposure to TNF inhibitor therapy is associated 
with an increased risk of SA in patients with RA. This risk seen in 
this study was greatest in the ﬁ  rst year of treatment. Joint pros-
thesis is a key risk factor for infection. Careful vigilance for joint 
infections in anti-TNF patients remains important, especially in 
the early months of therapy, with awareness of the potential 
range of pathogens that may be responsible. Antibiotic guide-
lines should incorporate this information and consider giving 
speciﬁ  c advice for patients being actively treated with anti-TNF 
agents. Current evidence does not support any one anti-TNF 
agent having a safer proﬁ  le with regard to SA.               
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 Table  3     Baseline  patient  characteristics  
  Number of patients with 
prosthetic joints   nbDMARD  (n=659)   Anti-TNF  (n=2689) 
Exposure time (years)* 1954 12 959
Events 6 41
Incidence prosthetic joint SA/1000 
pyrs (95% CI)
3.1 (1.1 to 6.7) 3.2 (2.3 to 4.3)
Adjusted HR (95% CI) Ref 1.2 (0.4 to 3.4)
      *Patients were included in this analysis only if they had a prosthetic joint in situ.   
    Anti-TNF, anti-tumour necrosis factor; nbDMARD, non-biological disease-modifying 
antirheumatic drug; pyrs, patient years.     
 Figure  2        Spline model showing changing risk of septic arthritis over 
time in the anti-TNF cohort. Anti-TNF, anti-tumour necrosis factor.       
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